|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
CO-ADMINISTRATION WITH DRUGS HAVING NARROW THERAPEUTIC INDEX SHOULD BE APPROACHED WITH CAUTION AS IT MAY CAUSE EARLY & SEVERE SIDE EFFECTS
|
POSSIBLE INCREASE IN SERIOUS TOXICITY WHEN AMIODARONE IS USED WITH OTHER ANTIARRHYTHMICS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CO-ADMINISTRATION HAS RESULTED IN ONE REPORT OF CARDIOPULMONARY ARREST, WITH FULL RECOVERY, IN A PATIENTS; A THEORETICAL POSSIBILITY THAT CO-ADMINISTRATION OF BETA-BLOCKER, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL
|
CIMETIDINE DECREASES RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED PLASMA LEVELS
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM WITH AN INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM WITH AN INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|